MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 886 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
B-Raf IN 1
CAS:<p>B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor.</p>Fórmula:C29H24F3N5OPureza:97.22% - 99.27%Forma y color:SolidPeso molecular:515.53CAY10404
CAS:<p>CAY10404: potent COX-1/2 inhibitor; blocks PKB/Akt, MAPK pathways; triggers NSC-LC apoptosis; analgesic, anti-inflammatory, anti-cancer.</p>Fórmula:C17H12F3NO3SPureza:99.02%Forma y color:SolidPeso molecular:367.34N-tert-butyl-α-Phenylnitrone
CAS:<p>N-tert-butyl-α-Phenylnitrone ((Z)-N-benzylidene-2-Methylpropan-2-aMine oxide) inhibits COX2 catalytic activity.</p>Fórmula:C11H15NOPureza:99.46% - 99.84%Forma y color:SolidPeso molecular:177.24Refametinib
CAS:<p>Refametinib (RDEA119) (RDEA119, Bay 86-9766) is an effective, ATP non-competitive and specific inhibitor of MEK1/2 (IC50: 19/47 nM).</p>Fórmula:C19H20F3IN2O5SPureza:99.53% - >99.99%Forma y color:SolidPeso molecular:572.34JNK Inhibitor VIII
CAS:<p>JNK Inhibitor VIII (TCS JNK 6o) is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2,</p>Fórmula:C18H20N4O4Pureza:98.93%Forma y color:SolidPeso molecular:356.38UM-164
CAS:<p>UM-164 (DAS-DFGO-II), a highly potent c-Src inhibitor with a dissociation constant (Kd) of 2.7 nM, also effectively inhibits p38α and p38β.</p>Fórmula:C30H31F3N8O3SPureza:98.72% - 99.52%Forma y color:SolidPeso molecular:640.68NG25 trihydrochloride
CAS:<p>NG25 trihydrochloride: kinase inhibitor for MAP4K2, TAK1, Src, LYN, Abl, CSK, FER, p38α; blocks TNF-α signals; impedes IFN secretion; anti-cancer properties.</p>Fórmula:C29H33Cl3F3N5O2Forma y color:SolidPeso molecular:646.96I-49 free base
<p>I-49 free base (Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-6-(tetrahydro-2H-pyran-4-yl)-) is a novel</p>Fórmula:C23H26ClF3N4O2Pureza:99.64% - 99.88%Forma y color:SolidPeso molecular:482.92Ulixertinib
CAS:<p>Ulixertinib (VRT752271) (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.</p>Fórmula:C21H22Cl2N4O2Pureza:99.31% - 99.95%Forma y color:SolidPeso molecular:433.33VX-11e
CAS:<p>VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.</p>Fórmula:C24H20Cl2FN5O2Pureza:98.92% - ≥98%Forma y color:SolidPeso molecular:500.35AD80
CAS:<p>AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.</p>Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Forma y color:SolidPeso molecular:473.43SB 239063
CAS:<p>SB 239063 (SB239063) is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.</p>Fórmula:C20H21FN4O2Pureza:99.42% - 99.81%Forma y color:SolidPeso molecular:368.4K-Ras(G12C) inhibitor 6
CAS:<p>Irreversible K-Ras(G12C) inhibitor 6 fully modifies the protein at 10 μM after 24h in vitro.</p>Fórmula:C17H22Cl2N2O3SPureza:89.07% - 97.09%Forma y color:SolidPeso molecular:405.34AS601245
CAS:<p>AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK), with neuroprotective properties.</p>Fórmula:C20H16N6SPureza:98% - 99.02%Forma y color:SolidPeso molecular:372.45Talmapimod
CAS:<p>Talmapimod (SCIO-469): Oral ATP-competitive p38α inhibitor, IC50 = 9 nM (p38α), 90 nM (p38β), >2000-fold selectivity over 20 kinases.</p>Fórmula:C27H30ClFN4O3Pureza:98% - 99.9%Forma y color:SolidPeso molecular:513Butein
CAS:<p>Butein is a cAMP-specific PDE inhibitor, protein tyrosine kinase inhibitor, and SIRT1 activator.Cost-effective and quality-assured.</p>Fórmula:C15H12O5Pureza:98.76% - >99.99%Forma y color:SolidPeso molecular:272.25D-JNKI-1 acetate
<p>D-JNKI-1 acetate (AM-111 acetate) is a highly potent and cell-permeable peptide inhibitor of JNK.</p>Fórmula:C166H290N66O42Pureza:99.48%Forma y color:SolidPeso molecular:3882.5Encorafenib
CAS:<p>Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.</p>Fórmula:C22H27ClFN7O4SPureza:99.51% - 99.83%Forma y color:SolidPeso molecular:540.01CCT196969
CAS:<p>CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.</p>Fórmula:C27H24FN7O3Pureza:98.93% - 99.65%Forma y color:SolidPeso molecular:513.52SD 0006
CAS:<p>SD 0006 (SD-06) is a MAPK p38 alpha inhibitor( IC50 : 110 nM) for the treatment of arthritis.</p>Fórmula:C20H20ClN5O2Pureza:98.32%Forma y color:SolidPeso molecular:397.86Cefotetan
CAS:<p>Cefotetan, a cephamycin antibiotic, fights various bacteria by disrupting cell wall synthesis.</p>Fórmula:C17H17N7O8S4Pureza:95.72% - 99.38%Forma y color:SolidPeso molecular:575.62ML-098
CAS:<p>ML-098 (CID-7345532) is an activator of the GTP-binding protein Rab7 (EC50: 77.6 nM).</p>Fórmula:C19H19NO3Pureza:99.06% - 99.23%Forma y color:SolidPeso molecular:309.36AZ7550
CAS:<p>AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Fórmula:C27H31N7O2Pureza:97.07% - 99.75%Forma y color:SolidPeso molecular:485.58Deltarasin HCl
CAS:<p>Deltarasin hinders KRAS-PDEδ, impairs cancer cell growth via a PDEδ pocket, disrupting RAS/RAF signaling and autophagy.</p>Fórmula:C40H37N5O·xHClForma y color:SolidPeso molecular:713.144GSK-114
CAS:<p>GSK-114, a TNNI3K inhibitor with a 25 nM IC50, is 40x more selective than B-Raf and good for in vivo studies.</p>Fórmula:C19H23N5O4SPureza:99.51%Forma y color:SolidPeso molecular:417.48JNK-IN-7
CAS:<p>JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).</p>Fórmula:C28H27N7O2Pureza:98.02% - 99.53%Forma y color:SolidPeso molecular:493.56K-Ras(G12C) inhibitor 9
CAS:<p>K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).</p>Fórmula:C16H21ClIN3O4SPureza:97.33% - 97.45%Forma y color:SolidPeso molecular:513.78Pyridoxal 5'-phosphate hydrate
CAS:<p>Pyridoxal 5'-phosphate hydrate (PLP)(1:x), the active form of vitamin B6, is a cofactor for many different enzymes involved in transamination reactions,</p>Fórmula:C8H10NO6PPureza:97.52%Forma y color:SolidPeso molecular:247.14PF-06260933
CAS:<p>PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.</p>Fórmula:C16H13ClN4Pureza:99.63% - 99.97%Forma y color:SolidPeso molecular:296.75GW284543
CAS:<p>GW284543 (UNC10225170) is a selective inhibitor of MEK5 .</p>Fórmula:C23H20N2O3Pureza:99.75%Forma y color:SolidPeso molecular:372.42ERK-IN-4
CAS:<p>ERK-IN-4 is a cell-permeable ERK inhibitor with potential antiproliferative effects for the study of diseases caused by immune dysfunction.</p>Fórmula:C14H17ClN2O3SPureza:98.92% - 99.84%Forma y color:SolidPeso molecular:328.814Raf inhibitor 1
CAS:<p>B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor.</p>Fórmula:C26H19ClN8Pureza:98.05%Forma y color:SolidPeso molecular:478.94Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Forma y color:SolidPeso molecular:482Ulixertinib hydrochloride
CAS:<p>Ulixertinib hydrochloride (Ulixertinib HCl) is an ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis</p>Fórmula:C21H23Cl3N4O2Pureza:99.85%Forma y color:SolidPeso molecular:469.79NCB-0846
CAS:<p>NCB-0846 is an orally active TNIK inhibitor (IC50: 21 nM).</p>Fórmula:C21H21N5O2Pureza:97.04% - 99.89%Forma y color:SolidPeso molecular:375.42TBAP-001
CAS:TBAP-001 is a RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay and an IC50 of 18 nM in Cell-Based Phosho-ERK Assay.Fórmula:C27H23F2N7O3Pureza:99.58%Forma y color:SolidPeso molecular:531.51VX-702
CAS:<p>VX-702: selective p38α MAPK inhibitor, potent anti-cytokine for rheumatoid arthritis.</p>Fórmula:C19H12F4N4O2Pureza:99% - >99.99%Forma y color:SolidPeso molecular:404.32Trametiglue
CAS:<p>Trametiglue, a potent Trametinib derivative, selectively targets KSR-MEK and RAF-MEK through unique binding.</p>Fórmula:C25H24FIN6O5SForma y color:SolidPeso molecular:666.46AZD0022
CAS:<p>AZD0022 is a selective, reversible, and orally active KRAS G12D inhibitor, exhibits tumour marker inhibition in PDAC and NSCLC models.</p>Fórmula:C34H30F4N6OPureza:98.73%Forma y color:SoildPeso molecular:614.64AMG410
CAS:<p>AMG410 is a non-covalent, dual-modality KRAS inhibitor effective against both GDP (OFF) and GTP (ON) binding independently of the cell cycle and other mutants,</p>Fórmula:C31H32ClF2N7O5Pureza:98.01% - 99.84%Forma y color:SoildPeso molecular:656.08SC-68376
CAS:<p>SC-68376 is a potent, reversible, cell-permeable, ATP-competitive, and selective inhibitor of p38 MAP kinase.</p>Fórmula:C15H12N2OPureza:98%Forma y color:SolidPeso molecular:236.27Deltarasin
CAS:<p>Deltarasin is a small molecular inhibitor of KRAS-PDEδ interaction with Kd of 38 nM for binding to purified PDEδ.</p>Fórmula:C40H37N5OPureza:99.4%Forma y color:SolidPeso molecular:603.75Cephradine monohydrate
CAS:<p>Cephradine monohydrate is a β-lactam cephalosporin antibiotic exhibiting broad-spectrum activity against Gram-positive and Gram-negative pathogens.</p>Fórmula:C16H21N3O5SPureza:99.91%Forma y color:SolidPeso molecular:367.42ETC-168
CAS:<p>ETC-168 is a selective, orally active MNK inhibitor with IC50 values of 23 nM for MNK1 and 43 nM for MNK2. It demonstrates antiproliferative efficacy both in vivo and in vitro [1].</p>Fórmula:C24H19N5O2Forma y color:SolidPeso molecular:409.44FMK
CAS:<p>FMK 是一种不可逆的 RSK2 抑制剂，能够共价修饰 RSK 的 C 末端区域。</p>Fórmula:C18H19FN4O2Pureza:99.71%Forma y color:SolidPeso molecular:342.376H05
CAS:<p>6H05 (K-Ras inhibitor) is a selective, allosteric inhibitor of oncogenic mutant K-Ras(G12C).</p>Fórmula:C20H30ClN3O2S3Pureza:98%Forma y color:SolidPeso molecular:476.12Sulindac sulfide
CAS:<p>Sulindac sulfide: NSAID targeting COX-1, inhibits Ras-Raf-1 and gamma-secretase (IC50: 20.2 μM), active sulinic acid metabolite.</p>Fórmula:C20H17FO2SPureza:99.35%Forma y color:SolidPeso molecular:340.41PLX7904
CAS:<p>PLX7904 (PB04), a selective RAF inhibitor, blocks ERK1/2 in mutant BRAF melanoma without activating it in RAS mutants.</p>Fórmula:C24H22F2N6O3SPureza:99.51% - 99.66%Forma y color:SolidPeso molecular:512.53CP-281384
CAS:<p>CP-281384 is a potent, p38alpha-selective inhibitor.</p>Fórmula:C18H14F2N4OPureza:98%Forma y color:SolidPeso molecular:340.33BRAF inhibitor
CAS:<p>BRAF inhibitor is an inhibitor of B-Raf.</p>Fórmula:C22H18F2N4O3SPureza:98.2% - 98.41%Forma y color:SolidPeso molecular:456.47ERK1/2 inhibitor 1
CAS:<p>ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively.</p>Fórmula:C29H32ClN5O4Pureza:98.81%Forma y color:SolidPeso molecular:550.05PF-05381941
CAS:<p>PF-05381941 is a selective and potent dual inhibitor of TAK1 and p38α that inhibits the kinase activity of TAK1 by binding to its active site.</p>Fórmula:C27H26N6O2Pureza:98.04%Forma y color:SolidPeso molecular:466.53MEK-IN-1
CAS:<p>MEK-IN-1 is a MEK inhibitor.</p>Fórmula:C24H20N4O4Pureza:98%Forma y color:SolidPeso molecular:428.44PAF (C16)
CAS:<p>PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability.</p>Fórmula:C26H54NO7PPureza:98%Forma y color:SolidPeso molecular:523.68B-Raf IN 13
CAS:<p>B-Raf IN 13 is a potent B-Raf inhibitor with anticancer activity.B-Raf IN 13 has an IC50 of 3.55 nM in the BRAF V600E enzyme assay.</p>Fórmula:C19H19ClFN3O4SPureza:99.41% - >99.99%Forma y color:SoildPeso molecular:439.89KRAS G12D inhibitor 10
CAS:<p>KRAS G12D inhibitor 10 targets KRAS G12D in cancer research (WO2021108683A1, compound 34).</p>Fórmula:C33H41ClN8O2Forma y color:SolidPeso molecular:617.18GGTI-286
CAS:<p>GGTI-286: GGTase I inhibitor, cell-permeable, IC50=2μM. Strongly blocks Rap1A geranylation; less effective on H-Ras, Ras4B IC50=1μM.</p>Fórmula:C23H31N3O3SForma y color:SolidPeso molecular:429.58MCP110
CAS:<p>MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors.</p>Fórmula:C33H36N2O3Pureza:97.23%Forma y color:OilPeso molecular:508.65KYA1797
CAS:<p>KYA1797 inhibits Wnt/ß-catenin, targeting axin, and promotes ß-catenin/Ras decay, halting APC/KRAS mutant CRC growth.</p>Fórmula:C17H12N2O6S2Pureza:98%Forma y color:SolidPeso molecular:404.42RSK2-IN-2
CAS:<p>RSK2-IN-2 (Compound 25) is a reversible covalent inhibitor of the RPS6KA3 ( RSK2 ) kinase which also inhibits MSK1, MSK2, and RSK3 [1].</p>Fórmula:C16H11N5OForma y color:SolidPeso molecular:289.29GABAB receptor antagonist 1
CAS:<p>(E)-GABAB receptor antagonist 1 decreases GABA-induced IP3 (inositol trisphosphate) production with IC50 of 37.9 μM.GABAB receptor antagonist 1 is a selective</p>Fórmula:C18H24O4Pureza:98%Forma y color:SolidPeso molecular:304.38B-Raf IN 8
CAS:<p>B-Raf IN 8: strong B-Raf inhibitor (70.65 nM IC50); combats liver, colon, breast & prostate cancer with IC50s from 9.78 to 29.85 μM.</p>Fórmula:C18H17N3O2Forma y color:SolidPeso molecular:307.35HPK1-IN-24
CAS:<p>HPK1-IN-24 (example 51) has potential to be used in the cancer research which is an inhibitor of hematopoietic progenitor kinase 1 (HPK1) (Ki = 100 nM) [1].</p>Fórmula:C19H14FN5Forma y color:SolidPeso molecular:331.35UC-857993
CAS:<p>UC-857993 is a selective SOS1-Ras inhibitor with a Kd of 14.7 μM that inhibits ERK, Ras, and reduces MEF growth.</p>Fórmula:C25H22ClNO2Forma y color:SolidPeso molecular:403.9JNK3 inhibitor-2
CAS:<p>JNK3 inhibitor-2: selectively inhibits JNK3 (IC50 = 0.25 μM); less effective on JNK1/JNK2 (>100 μM); targets DDR1 and EGFR mutations.</p>Fórmula:C20H14N2O2Forma y color:SolidPeso molecular:314.34Tpl2 Kinase Inhibitor 1
CAS:<p>Tpl2 Kinase Inhibitor 1 is an effective and selective Tpl2 inhibitor.</p>Fórmula:C21H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:404.83SX 011
CAS:<p>SX 011 is a p38α inhibitor.</p>Fórmula:C26H27ClFN3O3Pureza:98%Forma y color:SolidPeso molecular:483.96KRAS inhibitor-7
CAS:<p>KRAS inhibitor-7 is a potent KRAS G12C inhibitor.</p>Fórmula:C26H27ClF2N6O2Pureza:98%Forma y color:SolidPeso molecular:528.98HPK1-IN-25
CAS:<p>HPK1-IN-25, an HPK1 inhibitor, IC50 129 nM, may aid cancer research.</p>Fórmula:C23H25N5OForma y color:SolidPeso molecular:387.48KRAS G12C inhibitor 43
CAS:<p>KRAS G12C inhibitor 43 strongly blocks KRAS G12C, H358 cell growth (IC50: 0.001-1μM), less effective on A549, HCC cells (IC50>1μM).</p>Fórmula:C33H35N7O3Forma y color:SolidPeso molecular:577.68GGTI-286 hydrochloride
CAS:<p>GGTI-286 HCl strongly inhibits GGTase I (IC50: 2 μM) and K-Ras4B farnesylation (IC50: 1 μM).</p>Fórmula:C23H32ClN3O3SForma y color:SolidPeso molecular:466.04SMAP-2
CAS:<p>SMAP-2: oral PP2A activator, targets Aα subunit, halts KRAS-mutant lung cancer growth.</p>Fórmula:C27H27F3N2O4SPureza:98%Forma y color:SolidPeso molecular:532.57HPK1-IN-26
CAS:<p>HPK1-IN-26, from WO2021254118A1, is a potent dual HPK1/GLK inhibitor for studying animal infections.</p>Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47ZINC09659342
CAS:<p>ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction (IC50: 3.6 μM).</p>Fórmula:C23H15F3N2O4Forma y color:SolidPeso molecular:440.37NSC-658497
CAS:<p>NSC-658497 is a SOS1-Ras interaction inhibitor that acts by dose-dependently inhibiting SOS1 GEF activity.</p>Fórmula:C20H10N2O6S2Pureza:98%Forma y color:SolidPeso molecular:438.43SR 3576
CAS:<p>JNK3 inhibitor, potent and selective</p>Fórmula:C27H27N5O5Pureza:98%Forma y color:SolidPeso molecular:501.53CAY10561
CAS:<p>CAY10561: potent, selective ERK2 inhibitor (Ki=2nM); blocks cell proliferation; IC50 in COLO 205 cells: 0.54μM.</p>Fórmula:C22H17Cl2FN4O2Forma y color:SolidPeso molecular:459.3KRAS G12C inhibitor 22
CAS:<p>KRAS G12C inhibitor 22 is a KRAS G12C inhibitor.</p>Fórmula:C32H41N7O2Forma y color:SolidPeso molecular:555.71Quazinone
CAS:<p>Quazinone: PDE3 inhibitor, enhances heart muscle contractility, lowers blood pressure, and inhibits DNA synthesis in muscle cells. IC50 = 4.2 μM.</p>Fórmula:C11H10ClN3OForma y color:SolidPeso molecular:235.67SB-747651A
CAS:<p>SB-747651A: ATP-competitive MSK1 inhibitor (IC50=11nM), affects N-terminal domain, also hinders MSK2, PKA, PKB, RSK, p70S6K.</p>Fórmula:C16H22N8OPureza:98%Forma y color:SolidPeso molecular:342.4EO 1428
CAS:<p>p38α and p38β2 inhibitor</p>Fórmula:C20H16BrClN2OPureza:98%Forma y color:SolidPeso molecular:415.71PD 334581
CAS:<p>MEK1 inhibitor</p>Fórmula:C20H19F3IN5O2Pureza:98%Forma y color:SolidPeso molecular:545.3p38α inhibitor 2
CAS:<p>P38α Inhibitor 2, a potent and selective inhibitor of p38α MAPK, exhibits a pIC50 value of 9.6.</p>Fórmula:C27H33N5O3Forma y color:SolidPeso molecular:475.58pan-KRAS-IN-16
CAS:<p>3344 is an inhibitor of KRAS-effector interactions，with an affnity of 126nm.</p>Fórmula:C24H26N2O3Pureza:98%Forma y color:SolidPeso molecular:390.47B-Raf IN 6
CAS:<p>B-Raf IN 6: potent B-Raf kinase inhibitor, IC50 of 1.7 nM, doesn't target PXR, metabolically stable, potential in cancer research.</p>Fórmula:C24H21F3N6O2S2Forma y color:SolidPeso molecular:546.59(R)-CE3F4
CAS:<p>(R)-CE3F4 is a selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1)(IC50 of 4.2 μM),</p>Fórmula:C11H10Br2FNOForma y color:SolidPeso molecular:351.01SR-3737
CAS:<p>SR-3737 is potent both JNK3 and p38 inhibitor.</p>Fórmula:C29H25FN4O4Pureza:98%Forma y color:SolidPeso molecular:512.53TOPK-p38/JNK-IN-1
CAS:<p>TOPK-p38/JNK-IN-1 (Compound B12) is an orally active inhibitor of the TOPK-p38/JNK signaling pathway, with an IC50 value of 2.14 μM for the inhibition of NO</p>Fórmula:C17H15F3N2O4Forma y color:SolidPeso molecular:368.31B-Raf IN 7
CAS:<p>"B-Raf IN 7 inhibits B-Raf (IC50: 110.23 nM); fights colon, breast, liver, cervical, prostate cancers (IC50: 7.50-12.83 μM)."</p>Fórmula:C15H16N6O3Forma y color:SolidPeso molecular:328.33KB-5246
CAS:<p>KB-5246, displays antibacterial activities.is a tetracyclic quinolone.</p>Fórmula:C18H17ClFN3O4SPureza:98%Forma y color:SolidPeso molecular:425.86KRas G12C inhibitor 4
CAS:KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.Fórmula:C33H38ClN7O2Pureza:98%Forma y color:SolidPeso molecular:600.15Avutometinib potassium
CAS:<p>Avutometinib potassium, a MEKi, blocks Delta and Omicron infection in airway cells, potentially lessening disease severity.</p>Fórmula:C21H17FKN5O5SForma y color:SolidPeso molecular:509.553,4-Dephostatin
CAS:<p>3,4-Dephostatin is an inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95/Dlg1/ZO-1 (PDZ) domain.</p>Fórmula:C7H8N2O3Forma y color:SolidPeso molecular:168.15ERK5-IN-3
CAS:<p>ERK5-IN-3 inhibits ERK5 strongly (IC50: 6 nM) and hampers Hela cell growth (IC50: 31 nM).</p>Fórmula:C24H23Cl2FN4O2Forma y color:SolidPeso molecular:489.37Ras modulator-1
CAS:<p>Ras modulator-1 is a modulator of Ras.</p>Fórmula:C29H21N5O4SForma y color:SolidPeso molecular:535.57KRas G12C inhibitor 3
CAS:<p>KRas G12C inhibitor 3 is a compound that inhibits KRas G12C.</p>Fórmula:C32H36ClN7O2Pureza:98%Forma y color:SolidPeso molecular:586.13MW108
CAS:<p>MW108 is an active site targeted, CNS-active, p38αMAPK inhibitor.</p>Fórmula:C21H19ClN4Forma y color:SolidPeso molecular:362.86(S)-CCG-1423
<p>(S)-CCG-1423, a stereoisomer, inhibits Rho to block myocardin-related transcription factor A & serum response signaling.</p>Fórmula:C18H13ClF6N2O3Pureza:98%Forma y color:SolidPeso molecular:454.8K-Ras G12C-IN-3
CAS:<p>K-Ras G12C-IN-3: novel, irreversible inhibitor of K-Ras G12C mutant protein for cancer treatment.</p>Fórmula:C21H19Cl3N2O3Forma y color:SolidPeso molecular:453.75ML 3403
CAS:<p>p38 MAPK inhibitor; IC50: 0.38μM. Reduces IL-1β & TNF-α release in PBMC assay; IC50: 0.039μM & 0.16μM.</p>Fórmula:C23H21FN4SForma y color:SolidPeso molecular:404.5CCG-232601
CAS:<p>CCG-232601 is a inhibitor of the Rho/MRTF/SRF transcriptional pathway.</p>Fórmula:C24H20ClF2N3O2Pureza:98%Forma y color:SolidPeso molecular:455.88Tinlorafenib
CAS:<p>Tinlorafenib (PF-07284890), a BRAFV600E/K inhibitor, is oral & CNS-permeable, used for BRAF-linked CNS tumors. IC50: 4.25/2.7 nM.</p>Fórmula:C19H19ClF2N4O3SForma y color:SolidPeso molecular:456.89PHT-7.3
CAS:<p>PHT-7.3 is a selective connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain inhibitor</p>Fórmula:C24H23N3O3SPureza:98%Forma y color:SolidPeso molecular:433.52BRAF V600E/CRAF-IN-1
CAS:<p>BRAF V600E/CRAF-IN-1: potent BRAF/CRAF inhibitor, induces cell cycle arrest and apoptosis in HCT-116 cells, promising for cancer research.</p>Fórmula:C25H17F6N3O2Forma y color:SolidPeso molecular:505.41KRAS inhibitor-6
CAS:<p>KRAS inhibitor-6 is a potent KRAS G12C inhibitor.</p>Fórmula:C27H30ClF2N5O3Pureza:98%Forma y color:SolidPeso molecular:546.01(R)-STU104
CAS:<p>(R)-STU104 is a TAK1-MKK3 protein-protein interaction (PPI) inhibitor. (R)-STU104 is a candidate compound for the treatment of ulcerative colitis.</p>Fórmula:C18H18O4Pureza:98.91% - 99.42%Forma y color:SolidPeso molecular:298.33REDX05358
CAS:<p>REDX05358: Selective pan RAF inhibitor for BRAF/RAS mutant tumors with high affinity, safety, and low paradoxical activation.</p>Fórmula:C26H21ClN4O3Forma y color:SolidPeso molecular:472.92KRAS inhibitor-3
CAS:<p>KRAS inhibitor-3 targets WT/oncogenic KRAS; high affinity (KD: 0.28-0.74 μM); disrupts KRAS-Raf interaction.</p>Fórmula:C25H27N5OForma y color:SolidPeso molecular:413.51Spiclomazine HCl
CAS:<p>Spiclomazine HCl induced apoptosis in pancreatic cancer cells, which was generally related to cell viability, migration, and invasion.</p>Fórmula:C22H25Cl2N3OS2Forma y color:SolidPeso molecular:482.49PF-04880594
CAS:<p>PF-04880594 is a potent and selective RAF inhibitor which inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 exhibits antitumor activity [1].</p>Fórmula:C19H16F2N8Forma y color:SolidPeso molecular:394.38KRAS G12C inhibitor 48
<p>KRAS G12C inhibitor 48: potent with IC50 639.91 nM; hampers H358, H23, A549 cell growth with IC50s of 0.796, 6.33, 16.14 µM, respectively.</p>Fórmula:C36H39ClN8O2Forma y color:SolidPeso molecular:651.2KRAS G12C inhibitor 31
CAS:<p>KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Forma y color:SolidPeso molecular:508.93Nek2-IN-6
CAS:<p>Nek2-IN-6 inhibitor .</p>Fórmula:C33H33F3N6O4SForma y color:SolidPeso molecular:666.71L-167307
CAS:<p>L-167307 is a p38 kinase inhibitor.</p>Fórmula:C22H17FN2OSPureza:98%Forma y color:SolidPeso molecular:376.45KRAS4b-IN-D14
CAS:<p>KRAS4b-IN-D14 inhibits oncogenic KRAS4b, shrinks tumors, and induces cancer cell apoptosis.</p>Fórmula:C24H24ClN5O4Forma y color:SolidPeso molecular:481.93HPK1-IN-15
CAS:<p>HPK1-IN-15 selectively inhibits HPK1, a MAP4K family kinase, potentially aiding in cancer treatment.</p>Fórmula:C24H21ClF3N5Forma y color:SolidPeso molecular:471.91KRAS G12D inhibitor 13
CAS:<p>KRAS G12D inhibitor 13 targets KRAS G12D-mediated cancers with potency (WO2021108683A1, cmpd 142).</p>Fórmula:C31H33F2N7O3Forma y color:SolidPeso molecular:589.64KRAS G12C inhibitor 42
CAS:<p>KRAS G12C inhibitor 42 targets KRAS G12C for potential cancer therapy. (Patent WO2020146613A1, compound 10)</p>Fórmula:C33H34FN7O2Forma y color:SolidPeso molecular:579.67p38-α MAPK-IN-4
CAS:<p>p38-α MAPK-IN-4 (Compound 69) is a selective inhibitor of p38α MAPK, demonstrating potent inhibition with an IC50 of 1.5 μM.</p>Fórmula:C17H13BrN2OForma y color:SolidPeso molecular:341.2LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Fórmula:C28H18F4N6O2SForma y color:SolidPeso molecular:578.54KRAS G12C inhibitor 39
CAS:<p>KRAS G12C inhibitor 39 effectively targets KRAS G12C, a key protein in cancer research.</p>Fórmula:C37H43N9O2Forma y color:SolidPeso molecular:645.8CBS-3595
CAS:<p>CBS-3595: potent p38α MAPK/PDE-4 dual inhibitor, strong anti-inflammatory, low toxicity.</p>Fórmula:C18H17FN4O2SPureza:98%Forma y color:SolidPeso molecular:372.42GP17
CAS:<p>GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.</p>Fórmula:C26H21F3N4OForma y color:SolidPeso molecular:462.47JNK-1-IN-1
CAS:<p>JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.</p>Fórmula:C24H22N6SForma y color:SolidPeso molecular:426.54ADTL-EI1712
CAS:<p>ADTL-EI1712: ERK1/2/5 inhibitor (ERK1 IC50=40.43nM, ERK5=64.5nM), blocks HL-60/MKN74 cell growth, not HeLa; effective in MKN74 mouse model.</p>Fórmula:C22H18Cl2N4O2S2Forma y color:SolidPeso molecular:505.44JX 401
CAS:<p>JX 401 is a p38α inhibitor.</p>Fórmula:C21H25NO2SPureza:98%Forma y color:SolidPeso molecular:355.49SB 204900
CAS:<p>SB 204900 inhibit the release of histamine and TNF-α from RBL-2H3 cells.</p>Fórmula:C18H17NO2Forma y color:SolidPeso molecular:279.33HPK1-IN-29
CAS:<p>"HPK1-IN-29 suppresses HPK1, boosting anti-tumor immunity; potential for immune disease research."</p>Fórmula:C26H18F3N5O2Forma y color:SolidPeso molecular:489.45DDO3711
CAS:<p>"DDO3711, a PHORC, links an ASK1 inhibitor to a PP5 activator, inhibiting ASK1 (IC50=164.1 nM), dephosphorylating p-ASK1, and showing anti-cancer potential."</p>Fórmula:C42H41N9O6Forma y color:SolidPeso molecular:767.83KRAS G12C inhibitor 29
CAS:<p>KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C23H21ClFN5O2Forma y color:SolidPeso molecular:453.98-CPT-2Me-cAMP, sodium salt
CAS:<p>8-CPT-2Me-cAMP sodium activates Epac GEFS, targets Rap1/2, has 2.2 μM EC50 for Epac1, doesn't activate PKA, and prompts Ca2+ release in β-cells.</p>Fórmula:C17H16ClN5NaO6PSForma y color:SolidPeso molecular:507.82SCH-53870
CAS:<p>SCH-53870 inhibits p21-hRas nucleotide exchange in vitro.</p>Fórmula:C18H18N2O4SForma y color:SolidPeso molecular:358.41KRAS inhibitor-16
CAS:<p>KRAS inhibitor-16 blocks KRAS G12C and p-ERK in cancer cells; potential for pancreatic, colorectal, lung cancer treatment. IC50: 0.457 μM.</p>Fórmula:C20H16Cl2FN3O2SForma y color:SolidPeso molecular:452.33SOS1-IN-12
CAS:<p>SOS1-IN-12 is a potent inhibitor of SOS1, acting on SOS1 (Ki: 0.11 nM) and on pERK (IC50: 47 nM).</p>Fórmula:C23H26F3N5Forma y color:SolidPeso molecular:429.48MTBT
CAS:<p>MTBT is the proliferation of cancer cells inhibitor. It induces cell cycle arrest and activates p38 MAPK.</p>Fórmula:C14H11NO2S2Forma y color:SolidPeso molecular:289.37ARS-2102
CAS:<p>ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research .</p>Fórmula:C28H31ClF2N6O2Forma y color:SolidPeso molecular:557.03ERK5-IN-4
CAS:<p>ERK5-IN-4 (34b) is a potent, specific ERK5 inhibitor; IC50: 77 nM full-length, 300 nM ΔTAD in HEK293 cells.</p>Fórmula:C16H11Cl2FN4O2Forma y color:SolidPeso molecular:381.19KRAS inhibitor-15
CAS:<p>KRAS inhibitor-15 blocks KRAS G12C and p-ERK in cancer cells; potent against pancreatic and lung cancers. IC50: 0.954 μM (KRAS), 2.03/>33.3 μM (p-ERK).</p>Fórmula:C20H17Cl2FN4OSForma y color:SolidPeso molecular:451.34(S)-p38 MAPK Inhibitor III
CAS:<p>(S)-p38 MAPK inhibitor III: a cell-permeable, methylsulfanylimidazole; IC50s: 0.90 µM for p38 MAPK, 0.37 µM TNF-α, 0.044 µM IL-1β.</p>Fórmula:C23H21FN4SForma y color:SolidPeso molecular:404.5(R)-PD 0325901CL
CAS:<p>(R)-PD 0325901CL, a PD 0325901CL isomer, is a MEK inhibitor used in cancer research, effective against cancer cells in vitro and in vivo.</p>Fórmula:C16H14ClF2IN2O4Forma y color:SolidPeso molecular:498.65RAS inhibitor Abd-7
CAS:<p>Abd-7: potent RAS inhibitor (Kd=51 nM) that blocks RAS-effector PPI, disrupting KRAS, NRAS Q61H, HRAS G12V signaling.</p>Fórmula:C23H25N3O3Forma y color:SolidPeso molecular:391.46RAF-IN-1
CAS:<p>RAF-IN-1: strong b/cRAF inhibitor; cRAF IC50=3.8 nM; bRAFwt IC50=36 nM; bRAFV600E IC50=29.4 nM; A375/H358 bRAFV600E GI50=3.4/2.9 nM.</p>Fórmula:C26H22F3N3O4Forma y color:SolidPeso molecular:497.47KRAS inhibitor-4
CAS:<p>KRAS inhibitor-4 developed as anticancer agents, is a potent KRAS inhibitor.</p>Fórmula:C30H39ClN8OPureza:98%Forma y color:SolidPeso molecular:563.14Anti-inflammatory agent 33
CAS:<p>Agent 33: potent p38α inhibitor, reduces NO, iNOS, COX-2, p-p38α, p-MK2; shows anti-inflammatory effects.</p>Fórmula:C22H15N3O5SForma y color:SolidPeso molecular:433.44RSK2-IN-3
CAS:<p>RSK2-IN-3 (Compound 26) is a covalent, reversible inhibitor of RPS6KA3 (RSK2) kinase.</p>Fórmula:C24H26N4O5Forma y color:SolidPeso molecular:450.49MLKL-IN-5
CAS:<p>MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .</p>Fórmula:C18H20N6O4SForma y color:SolidPeso molecular:416.45HPK1-IN-28
CAS:<p>HPK1-IN-28 inhibits HPK1, boosts anti-tumor immunity, and shows promise in immune disease research per patent WO2021175270A1.</p>Fórmula:C25H22F3N5O4Forma y color:SolidPeso molecular:513.47JTP-70902
CAS:<p>JTP-70902 is a protein kinase inhibitor with antineoplastic activity.</p>Fórmula:C24H21BrFN5O5SForma y color:SolidPeso molecular:590.42Antifungal agent 46
CAS:<p>Compound 2f (Antifungal Agent 46) is a potent antifungal that inhibits Ras signaling by targeting protein farnesyltransferase [1].</p>Fórmula:C26H28BrF3N4O2Pureza:98%Forma y color:SolidPeso molecular:565.43p38 MAP Kinase Inhibitor IV
CAS:<p>p38 MAPK inhibitor IV blocks p38α/β/γ/δ with IC50s 0.13-8.63 μM and stops TNF-α/IL-1β at 22/44 nM in human cells.</p>Fórmula:C12H4Cl6O4SForma y color:SolidPeso molecular:456.94KRAS inhibitor-10
CAS:<p>KRAS inhibitor-10: potent, selective KRAS protein blocker; effective in various cancers; oral; tetrahydroisoquinoline class.</p>Fórmula:C30H37N3O5Forma y color:SolidPeso molecular:519.63KRAS G12C inhibitor 45
CAS:<p>KRAS G12C inhibitor 45 is a potent KRAS G12C inhibitor .</p>Fórmula:C32H33F2N5O5SForma y color:SolidPeso molecular:637.7JNK3 inhibitor-4
CAS:<p>JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.</p>Fórmula:C28H27N7OForma y color:SolidPeso molecular:477.56HPK1-IN-17
CAS:<p>HPK1-IN-17 selectively inhibits HPK1, a MAP4Ks family kinase from blood progenitor cells; useful against HPK1-related diseases like cancer.</p>Fórmula:C26H28N6OForma y color:SolidPeso molecular:440.54KRAS inhibitor-17
CAS:<p>KRAS inhibitor-17 blocks G12C mutation (IC50: 3.37μM) and p-ERK in MIA PaCA-2 (IC50: 9.25μM). Could target pancreatic, colorectal, lung cancers.</p>Fórmula:C21H18Cl2FN3O2SForma y color:SolidPeso molecular:466.36BRAF V600E/CRAF-IN-2
CAS:<p>Potent BRAFV600E/CRAF inhibitor, IC50: 0.888/0.229 μM, induces G0/G1 arrest and apoptosis in HCT-116 cells, potential for cancer research.</p>Fórmula:C30H30F3N5O2Forma y color:SolidPeso molecular:549.59KRAS4b-PDEδ stabilizer C19
CAS:<p>KRAS4b-PDEδ stabilizer C19 is a stabilizer of the KRAS4b-PDEδ complex which decreases the proliferation of colorectal cancer cells, and increases apoptosis via</p>Fórmula:C18H20Cl2N2O3Forma y color:SolidPeso molecular:383.27SCH 51344
CAS:<p>SCH 51344 inhibits Ras induced malignant transformation. SCH 51344 prevents anchorage-independent growth of oncogene transformed fibroblasts [1].</p>Fórmula:C16H20N4O3Forma y color:SolidPeso molecular:316.36LX-3
CAS:<p>LX-3 activates p38 MAPK, enabling expression of genes normally silenced by DNA methylation.</p>Fórmula:C20H13BrN4OSForma y color:SolidPeso molecular:437.31KRAS G12C inhibitor 47
CAS:<p>KRAS G12C inhibitor 47 strongly blocks KRAS G12C (IC50: 0.172 μM) and p-ERK in cells; promising for pancreatic, colorectal, lung cancers.</p>Fórmula:C30H28ClFN4O3Forma y color:SolidPeso molecular:547.02SOS1-IN-3
CAS:<p>SOS1-IN-3 is an effective inhibitor of SOS1 (son of sevenless homolog 1) (IC50=5 nM). SOS1-IN-3 shows antitumor activity.</p>Fórmula:C21H21F3N4OForma y color:SolidPeso molecular:402.41SOS1 activator 1
CAS:<p>SOS1 activator 1 enhances SOS1's GDP-GTP exchange on Ras (Kd: 44 nM).</p>Fórmula:C26H32ClFN6Forma y color:SolidPeso molecular:483.026-T-GDP
CAS:<p>6-T-GDP (6-Thioguanosine 5'-diphosphate) is a metabolite of thiopurine. It inhibits the activity of Rac1, thereby reducing the transcription of inflammatory factors and the expression of cell adhesion molecules, which ultimately suppresses leukocyte migration and the occurrence of tissue inflammation.</p>Fórmula:C10H15N5O10P2SForma y color:SolidPeso molecular:459.27GDC-0879
CAS:<p>GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well.</p>Fórmula:C19H18N4O2Pureza:99.62%Forma y color:SolidPeso molecular:334.37Tpl2-IN-I
CAS:<p>Tpl2-IN-I is an inhibitor of tumour progression locus 2 (Tpl2) kinase.</p>Fórmula:C21H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:404.83NSC1011
CAS:<p>NSC1011 is an inhibitor of ras converting enzyme 1 (Rce1).</p>Fórmula:C23H18N2O3Pureza:98%Forma y color:SolidPeso molecular:370.4AZD6703 free base
CAS:<p>AZD6703 is a potent, selective and reversible orally bioavailable inhibitor of p38 mitogen-activated protein kinase 14 (MAPK14).</p>Fórmula:C24H27N5O2Forma y color:SolidPeso molecular:417.5Kobe2601
CAS:<p>Kobe2601 is a Kobe0065 and Kobe02602 water-soluble analog. It displays inhibitory activity towards Ras-Raf binding.</p>Fórmula:C13H10FN5O4SPureza:98%Forma y color:SolidPeso molecular:351.31GSK329
CAS:<p>GSK329 selectively inhibits TNNI3K, showing cardioprotection in ischemic heart models.</p>Fórmula:C19H14Cl2F3N5O2Pureza:98%Forma y color:SolidPeso molecular:472.25HCI-2184
CAS:<p>HCI-2184 is an inhibitor of AXL kinase and Nek2 that acts by successfully mitigating drug resistance in bortezomib-resistant multiple myeloma.</p>Fórmula:C23H28ClN7O2SPureza:98%Forma y color:SolidPeso molecular:502.03GSK649A
CAS:<p>GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.</p>Fórmula:C15H12ClFN6OSPureza:98%Forma y color:SolidPeso molecular:378.81RBC6
CAS:<p>RBC6 is an inhibitor of the binding of Ral to its effector RALBP1.</p>Fórmula:C16H14Cl2N4O2Pureza:98%Forma y color:SolidPeso molecular:365.21CP-944629
CAS:<p>CP-944629 is a novel, potent, and selective inhibitor of p38alpha.</p>Fórmula:C19H15F3N4OPureza:98%Forma y color:SolidPeso molecular:372.34BNC-1
CAS:<p>BNC-1 reduces amyloid in mice, enhances synapses by activating Elk-1.</p>Fórmula:C16H14N2O3Pureza:98%Forma y color:SolidPeso molecular:282.29BSJ-04-122
CAS:<p>BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM & 181 nM, used in cancer research.</p>Fórmula:C15H12ClN5OPureza:97.61%Forma y color:SolidPeso molecular:313.74CK1-IN-2
CAS:<p>CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor p38a, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.</p>Fórmula:C17H12FN3O2Pureza:99.31%Forma y color:SolidPeso molecular:309.29SR-3306
CAS:<p>SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.</p>Fórmula:C28H26N8OPureza:99.38% - 99.71%Forma y color:SolidPeso molecular:490.56GNE-1858
CAS:<p>GNE-1858 inhibits HPK1; IC50: 1.9 nM for wild-type, 1.9 nM (HPK1-TSEE), 4.5 nM (HPK1-SA).</p>Fórmula:C21H26F2N8Pureza:99.36%Forma y color:SolidPeso molecular:428.48J30-8
CAS:<p>J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.</p>Fórmula:C17H9ClFN3O2SPureza:99.90%Forma y color:SolidPeso molecular:373.79TAK1/MAP4K2 inhibitor 1
CAS:<p>TAK1/MAP4K2 inhibitor 1 (compound 5) is a dual kinase inhibitor of TAK1 and MAP4K2 with IC50 values of 41.1 nM and 18.2 nM, respectively.</p>Fórmula:C29H31F3N6O2Pureza:98%Forma y color:SolidPeso molecular:552.59RMM-46
CAS:<p>RMM-46 is a reversible covalent inhibitor with high ligand efficiency and selectivity for MSK/RSK family kinases.</p>Fórmula:C24H26N4O5Pureza:98.89%Forma y color:SolidPeso molecular:450.49LY-2584702 hydrochloride
CAS:<p>Ly-2584702 hydrochloride is a p70S6K selective ATP competitive inhibitor with IC50 of 4 nM.In the S6K1 enzyme assay, the IC50 of LY-2584702 was 2 nM.</p>Fórmula:C21H20ClF4N7Pureza:98%Forma y color:SolidPeso molecular:481.88MEK inhibitor
CAS:<p>MEK inhibitor is a MEK receptor and cell cycle protein/CDK complex inhibitor with antitumor activity that can be used to study tumor cell proliferation.</p>Fórmula:C26H26N4O2Pureza:97.48%Forma y color:SolidPeso molecular:426.51NSC-70220
CAS:<p>SOS1-IN-1 is an inhibitor of SOS1.</p>Fórmula:C22H15NO2Pureza:98%Forma y color:SolidPeso molecular:325.36MNK1/2-IN-5
CAS:<p>MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor with anticancer activity and can be used to study solid tumors and hematological malignancies.</p>Fórmula:C17H16N4O2Pureza:98.04%Forma y color:SolidPeso molecular:308.33MEK-IN-4
CAS:<p>MEK-IN-4 is a MEK inhibitor that can be used to study inflammatory diseases and cancer.</p>Fórmula:C21H18N4OSPureza:98.35% - 99.16%Forma y color:SolidPeso molecular:374.46Nek2-IN-5
CAS:<p>Nek2-IN-5 (NCL00017509) is a potent and selective inhibitor of NIMA-related kinase 2 (Nek2).</p>Fórmula:C15H12N6OPureza:98.11%Forma y color:SolidPeso molecular:292.3mSIRK
CAS:<p>mSIRK (G-Protein βγ Binding Peptide) is an ERK1 and ERK2 dual activator that promotes alpha-subunit dissociation.</p>Fórmula:C93H150N20O25Pureza:99.26%Forma y color:SolidPeso molecular:1948.31p38α inhibitor 4
CAS:<p>p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.</p>Fórmula:C14H7F6N3OPureza:99.69%Forma y color:SolidPeso molecular:347.215UR13870
CAS:<p>UR-13870 (Org 48762-0) is a p38 MAPK inhibitor that prevents bone damage in collagen-induced arthritis in mice.</p>Fórmula:C24H16F2N4Pureza:99.18% - >99.99%Forma y color:SolidPeso molecular:398.41(E)-GABAB receptor antagonist 1
CAS:<p>(E)-GABAB antagonist 1 inhibits GABA IP3 production, with an IC50 of 37.9 μM and acts as a selective negative modulator.</p>Fórmula:C18H24O4Pureza:98.09%Forma y color:SolidPeso molecular:304.38GSK2008607
CAS:<p>GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.</p>Fórmula:C31H28F3N7O3S2Pureza:99.36%Forma y color:SolidPeso molecular:667.72EO-1606
CAS:<p>EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.</p>Fórmula:C21H17ClFNOPureza:98.28% - 98.84%Forma y color:SolidPeso molecular:353.82DS12881479
CAS:<p>DS12881479 can be used in cancer research which is a potent and selective inhibitor of Mnk1(IC 50 =21 nM) [1].</p>Fórmula:C16H19N3OSPureza:99.85%Forma y color:SolidPeso molecular:301.41RMC-0331
CAS:<p>RMC-0331 (RM-023) is an oral SOS1 inhibitor with potential to block RAS activation and anticancer properties.</p>Fórmula:C22H25ClF3N5O3Pureza:99.81%Forma y color:SolidPeso molecular:499.91MKK7-COV-9
CAS:<p>MKK7-COV-9 is an MKK7 inhibitor that inhibits MKK7-induced protein-protein interactions and interrupts the activation of primary B cells in response to LPS.</p>Fórmula:C18H16N4O2Pureza:99.07% - 99.73%Forma y color:SolidPeso molecular:320.35p38 MAPK Inhibitor
CAS:<p>p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.</p>Fórmula:C20H13ClFN3OPureza:99.91%Forma y color:SolidPeso molecular:365.79ZINC12409120
CAS:<p>ZINC12409120 (R-4584) is a selective ERK inhibitor.ZINC12409120 inhibits ERK with an IC50 of 5.0 μM.ZINC12409120 inhibits ERK activity by interfering with FGF23</p>Fórmula:C20H16N4O2Pureza:99.71% - 99.95%Forma y color:SolidPeso molecular:344.37BI-2852
CAS:<p>BI-2852: nanomolar affinity KRAS switch I/II pocket inhibitor; blocks signaling, halts KRAS mutant cell growth.</p>Fórmula:C31H28N6O2Pureza:98.98%Forma y color:SolidPeso molecular:516.59JNK-IN-11
CAS:<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>Fórmula:C12H11NO3S2Pureza:98.82%Forma y color:SolidPeso molecular:281.35
